US4071619A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Method of producing vaccines
Assignee: Individual
•
Filing: 1976-09-02
•
Granted: 1978-01-31
•
Expires: 1996-09-02
Abstract
Abstract A method for producing vaccines wherein a suspension of the viral culture is purified by gel chromatography in a column packed with a porous virion non-sorbing silicate material having pore diameter of 50 to 10000 A, followed by adsorption-elution concentration and completion of the vaccine, or the starting suspension of the viral culture is concentrated by adsorption-elution and then purified by gel chromatography in a column packed with porous silicate material having pore diameter of 50 to 10000 A, or the starting suspension of the viral culture is subjected to gel chromatography in a column filled with a porous silicate material having pore diameter of 50 to 10000 A and the final vaccine is produced.
Inventors
- 👤 Tamaz Vladimirovich Peradze
- 👤 Eidlya Abramovna Fridman
- 👤 Nina Vsevolodovna Zheleznova
- 👤 Vsevolod Mikhailovich Kolikov
- 👤 Semen Khaimovich-Efimovich Bresler
- 👤 Boris Viktorovich Mchedlishvili
- 👤 Viktor Mikhailovich Molodkin
- 👤 Ljudmila Mikhailovna Molodkina
- 👤 Nina Vasilievna Katushkina
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-11-08 03:03
CPC Classifications
A; A61; A61K; A61K39/00; A61K39/12; A61K39/125; A61K39/13; A61K39/145; A61K39/205; C; C12; C12N; C12N7/00; A61K2039/51; A61K2039/525; A61K2039/5252; C12N2760/00; C12N2760/00011; C12N2760/10011; C12N2760/10034; C12N2760/10051; C12N2760/16011; C12N2760/16111; C12N2760/16134; C12N2760/16151; C12N2760/20011; C12N2760/20111; C12N2760/20134; C12N2760/20151; Y; Y02; Y02A; Y02A50/00; Y02A50/30
Claims Analysis
Total Claims: 10
Claim 1
Independent Claim
149 words
A method for producing vaccines comprising purification of a viral culture by gel chromatography in columns packed with a porous silicate virion non-absorbing material having pore diameter of 50 to 10,000A, concentration by adsorption in columns packed with a porous silicate sorbent having a pore diameter of 50 to 10,000A and a porosity of 0.3 to 2.5 cm 3 /g, followed by virus desorption by means of buffer solutions having a pH of 6 to 10 in two steps using a gradient of ionic strength of from 0.1 to 1.0: a. at the beginning of the gradient, the columns are washed to eliminate the initial culture remaining between the sorbent granules, and b. at the end of the gradient, virions are desorbed, with subsequent transfer of the viral suspension into physiological conditions of pH 7 to 7.8 with NaCl concentration of 0.14-0.15 mole/1 and inactivation of the viral suspension.
Claim 2
Independent Claim
149 words
A method for producing vaccines comprising purification of a viral culture by gel chromatography in columns packed with a porous silicate virion non-absorbing material having pore diameter of 50 to 10,000A, concentration by adsorption in columns packed with a porous silicate sorbent having a pore diameter of 50 to 10,000A and a porosity of 0.3 to 2.5 cm 3 /g, followed by virus desorption by means of buffer solutions having a pH of 6 to 10 in two steps using a gradient of ionic strength of from 0.1 to 1.0: a. at the beginning of the gradient, the columns are washed to eliminate the initial culture remaining between the sorbent granules, and b. at the end of the gradient, virions are desorbed, with subsequent transfer of the viral suspension into physiological conditions of pH 7 to 7.8 with NaCl concentration of 0.14-0.15 mole/1 and inactivation of the viral suspension.
Claim 3
Dependent Claim
55 words
A method as claimed in claim 1, wherein the porous silicate material is a material selected from the group consisting of sodium-borosilicate glass and large-pore gels of silicic acid with a pore diameter of 300 to 2,000A, a porosity of 0.3 to 2.5 cm 3 /g and a grain size of 0.1 to 0.3 mm.
Claim 4
Dependent Claim
39 words
A method as claimed in claim 1, wherein the buffer solution is selected from the group consisting of phosphate buffers with a pH value of 6.0 to 8.2 and tris buffers with a pH value of 7.2 to 10.0.
Claim 5
Dependent Claim
31 words
A method as claimed in claim 1, wherein for separation of killed vaccinae the viral suspension is inactivated by ultra-violet irradiation in a dose of 5,000 to 200,000 erg/cm 2 .
Claim 6
Dependent Claim
35 words
A method as claimed in claim 1, wherein said transfer into physiological conditions is effected by gel chromatography in a column packed with a porous silicate material having a pore diameter of 50 to 10,000A.
Claim 7
Dependent Claim
16 words
A method according to claim 1, wherein the vaccines are antiinfluenza, antipoliomyelitis, antirabies, antiarboviral, antimyxoviral vaccines.
Claim 8
Independent Claim
167 words
A method for producing vaccines comprising concentration of a suspension of a viral culture by adsorption in columns packed with a porous silicate sorbent having a pore diameter of 50 to 10,000A and a porosity of 0.3 to 2.5 cm 3 /g, followed by the virus desorption by means of buffer solutions having a pH of 6.0 to 10.0 in two steps using a gradient of ionic strength of from 0.1 to 1.0: a. at the beginning of the gradient, the column is washed to eliminate the initial culture remaining between the sorbent granules, and b. at the end of the gradient, virions are desorbed from the sorbent granule surface; purification by gel-chromatography in a column packed with a porous silicate material having a pore diameter of 50 to 10,000A and granule size of 0.1 to 3 mm, with subsequent isolation of the vaccine by transferring the viral suspension into physiological conditions of pH 7.8 with NaCl concentration of 0.14-0.15 mole/1 and inactivation of the viral suspension.
Claim 9
Independent Claim
167 words
A method for producing vaccines comprising concentration of a suspension of a viral culture by adsorption in columns packed with a porous silicate sorbent having a pore diameter of 50 to 10,000A and a porosity of 0.3 to 2.5 cm 3 /g, followed by the virus desorption by means of buffer solutions having a pH of 6.0 to 10.0 in two steps using a gradient of ionic strength of from 0.1 to 1.0: a. at the beginning of the gradient, the column is washed to eliminate the initial culture remaining between the sorbent granules, and b. at the end of the gradient, virions are desorbed from the sorbent granule surface; purification by gel-chromatography in a column packed with a porous silicate material having a pore diameter of 50 to 10,000A and granule size of 0.1 to 3 mm, with subsequent isolation of the vaccine by transferring the viral suspension into physiological conditions of pH 7.8 with NaCl concentration of 0.14-0.15 mole/1 and inactivation of the viral suspension.
Claim 10
Dependent Claim
17 words
A method according to claim 7, wherein the vaccines are antiinfluenza, antipoliomyelitis, antirabies, antiarboviral, or antimyxoviral vaccines.
References Cited (Backward Citations)
No citation records indexed.
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1981-01-30 | 1981-08-01 | 1982-01-31 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1985-01-30 | 1985-08-01 | 1986-01-31 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 1989-01-30 | 1989-08-01 | 1990-01-31 | $7700.00 | Window Closed / Lapsed |